Skip to main content
. Author manuscript; available in PMC: 2011 May 15.
Published in final edited form as: Cancer Immunol Immunother. 2011 Feb 22;60(5):731–738. doi: 10.1007/s00262-011-0971-0

Fig. 3. Survival of mice receiving IC/RV combination therapy.

Fig. 3

NXS2 tumor-bearing mice were treated with DMSO p.t. (n=20), 20mg RV p.t.(n=20), IC i.v. (n=23) or IC/RV in combination (n=23). Mice were observed for survival for 100 days or until their primary tumor reached the size limit (15mm in any dimension) requiring euthanasia. Sixty-one % of the mice receiving IC/RV combination survived to day 100 with no detectable tumors compared to 15% and 13% of the mice in the RV-alone or the IC-alone group, respectively. There was a significant difference in overall survival among the four treatment groups (p<0.0001). Pair-wise comparisons of survival distribution over time: DMSO vs. RV: p=0.005, DMSO vs. IC: p=0.19, DMSO vs. IC/RV: p<0.0001, IC/RV vs. IC: p=0.0003, IC/RV vs. RV: p=0.001, RV vs. IC: p=0.16